Loading
A phase 2 trial of Atirmociclib, Letrozole, Fulvestrant in prostate cancer, run by Pfizer, active and no longer recruiting.
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors is a phase 2 interventional study registered as NCT04557449 by Pfizer, with 362 participants enrolled, started 2020-09-23 and due to reach its primary completion in 2026-09-23. Interventions recorded: PF-07220060, Letrozole, Fulvestrant, Midazolam, Enzalutamide. Conditions listed: Liposarcoma, Prostate Cancer, Breast Neoplasms, Adenocarcinoma of Lung. No results are recorded here; the registry entry is the source.
Shares Atirmociclib, Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Prostate cancer.
Shares Atirmociclib, Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Letrozole (and other aromatase inhibitors), Fulvestrant, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Atirmociclib, CDK4/6 inhibitors, Pfizer (incl. Seagen).
Shares Fulvestrant, CDK4/6 inhibitors, Pfizer (incl. Seagen).